Manitimus

DB06481InvestigationalSmall molecule

FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.

Mechanism: FK778 exerts its immunosuppressive activity at the molecular level via the suppression of de-novo pyrimidine biosynthesis, inhibiting the action of dihydroorotate dehydrogenase, an enzyme critical in the process, and consequently inhibiting cell proliferation.
Curator reviewed
Primary indication: Investigated for use/treatment in immunosuppressive and transplant (rejection).Curator reviewed
Formula / weight: C₁₅H₁₁F₃N₂O₂ · 308.26 g/mol (avg)
Also known as: (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide · (2Z)-2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHLY)PHENYL)-2-HEPTEN-6-YNAMIDE · (2Z)-2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)HEPT-2-EN-6-YNAMIDE · 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-2-HEPTEN-6-YNAMIDE
Code names: FK-778 · HMR-1715 · MNA-715

Resolves to

Compound

UNII4B135RK2KLCAS202057-76-9ChEMBLCHEMBL4754445

Structure

InChIKeyIRELROQHIPLASX-SEYXRHQNSA-NSMILESO\C(CCC#C)=C(\C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F

Targets

Q02127DHODH

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

Which drugs share a target with Manitimus, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account